Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Abemaciclib + Fulvestrant & Breast cancer / Mammacarcinoma (HR+ Her2-), the FDA has granted approval for the combination of Abemaciclib + Fulvestrant for women diagnosed with advanced or metastatic Breast cancer / Mammacarcinoma (HR+ Her2-), particularly for those whose disease has advanced after undergoing endocrine therapy. This decision is supported by the findings from the MONARCH-2 trial, which demonstrated a notable enhancement in progression-free survival when compared to the use of fulvestrant with a placebo in this context (1).
Abemaciclib is indicated by the [EMA](brain://QMGe2vnx…